Supriya Lifescience Limited — Updates, 28-05-2025: Press Release

Supriya Lifescience has announced a board meeting on the financial results for the quarter and half-year. FY25 revenue jumped 22% to Rs. 696.48 Cr, with EBITDA up 51% to Rs. 260.80 Cr and margin at 37.4%. PAT surged 58% to Rs. 187.96 Cr, lifting the PAT margin to 27%. Q4 saw revenues grow 16.4% to Rs. 184.11 Cr and PAT rise 38.4% to Rs. 50.38 Cr. Growth was driven by diversification, global expansion, and improved operational efficiency.